Rhumbline Advisers Grows Stake in Aerie Pharmaceuticals Inc (AERI)

Rhumbline Advisers grew its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 5.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 36,645 shares of the company’s stock after acquiring an additional 1,732 shares during the period. Rhumbline Advisers owned about 0.10% of Aerie Pharmaceuticals worth $1,781,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. lifted its stake in shares of Aerie Pharmaceuticals by 11.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock valued at $140,000 after buying an additional 275 shares in the last quarter. BNP Paribas Arbitrage SA lifted its stake in shares of Aerie Pharmaceuticals by 2,711.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after buying an additional 3,579 shares in the last quarter. Amalgamated Bank purchased a new stake in shares of Aerie Pharmaceuticals during the 2nd quarter valued at approximately $204,000. California Public Employees Retirement System purchased a new stake in shares of Aerie Pharmaceuticals during the 1st quarter valued at approximately $231,000. Finally, Aperio Group LLC lifted its stake in shares of Aerie Pharmaceuticals by 4.7% during the 2nd quarter. Aperio Group LLC now owns 4,914 shares of the company’s stock valued at $258,000 after buying an additional 219 shares in the last quarter.

Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) opened at $58.95 on Wednesday. Aerie Pharmaceuticals Inc has a 52 week low of $35.50 and a 52 week high of $66.60. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78.

A number of analysts recently commented on AERI shares. Canaccord Genuity set a $65.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 16th. Mizuho restated a “buy” rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. JMP Securities set a $68.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 11th. Cantor Fitzgerald reiterated a “buy” rating and issued a $62.00 target price on shares of Aerie Pharmaceuticals in a research note on Wednesday, October 11th. Finally, Cowen reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Thursday, October 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Aerie Pharmaceuticals presently has an average rating of “Buy” and an average target price of $71.43.

TRADEMARK VIOLATION WARNING: This story was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://ledgergazette.com/2017/12/13/rhumbline-advisers-grows-stake-in-aerie-pharmaceuticals-inc-aeri.html.

Aerie Pharmaceuticals Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply